rs1800628

▶

GWAS Catalog Trait Associations (9)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

interleukin-2 receptor subunit alpha measurement

Loya H et al. “A scalable variational inference approach for increased mixed-model association power.” Nature Genetics 57(2):461-468 (2025)
Allele A
OR 0.11
p 7.0e-67
N 47,745
Large GWAS
European

fatty acid amount

Sun Y et al. “GWAS and multi-omics integrative analysis reveal novel loci and their molecular mechanisms for circulating fatty acids.” Hgg Advances 6(4):100470 (2025)
Allele A
OR —
p 3.0e-20
N 128,922
Large GWAS
European

Inguinal hernia

Wei J et al. “Identification of fifty-seven novel loci for abdominal wall hernia development and their biological and clinical implications: results from the UK Biobank.” Hernia : the Journal of Hernias and Abdominal Wall Surgery 26(1):335-348 (2022)
Allele G
OR 1.10
p 1.0e-8
N 275,546
Major Consortium StudyLarge GWAS
European
▶

Research that mentions this SNP (1)

▶
Pathway‐analysis of published genome‐wide association studies of lung cancer: A potential role for the CYP4F3 locus
Meta-analysisN=30,778Jieyun Yin et al.(2017)· Molecular Carcinogenesis

Pathway-based meta-analysis of 6 GWAS studies from the TRICL consortium (12,160 lung cancer cases and 16,838 controls) combined with Harvard GWAS data identified CYP4F3 rs4646904 (G>A) as a potentially functional SNP associated with lung cancer risk (OR=1.07, 95%CI=1.03-1.12, P=3.52×10-3). The variant showed stronger association in smokers (OR=1.13, P=6.70×10-5) and is predicted to influence splicing efficiency of CYP4F3, a gene involved in fatty acid metabolism.

Traits studied:AdenocarcinomaLung cancerNon-small cell lung cancer (NSCLC)Squamous cell carcinoma
PubMedDOIMetascience Observatory

This variant is in our database but has no known associations or PRS memberships yet.

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…